UY30728A1 - Sales y formas de cristal del 2-metil-[4-(3-metil-2-oxo-8-quinolin-3-il-2,3-dihidro-imidazo-[4,5-c]-quinolin-1-il-fenil]propionitrilo - Google Patents
Sales y formas de cristal del 2-metil-[4-(3-metil-2-oxo-8-quinolin-3-il-2,3-dihidro-imidazo-[4,5-c]-quinolin-1-il-fenil]propionitriloInfo
- Publication number
- UY30728A1 UY30728A1 UY30728A UY30728A UY30728A1 UY 30728 A1 UY30728 A1 UY 30728A1 UY 30728 A UY30728 A UY 30728A UY 30728 A UY30728 A UY 30728A UY 30728 A1 UY30728 A1 UY 30728A1
- Authority
- UY
- Uruguay
- Prior art keywords
- quinolin
- methyl
- propionitrile
- imidazo
- dihydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invencion refiere a:Formas cristalinas particulares del 2-metíl-2[4-(3-metíl-2oxo-8-quinolin-3-il-2,3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo, sus hidratos y solvatos, sus sales e hidratos y solvatos de sus sales, procesos para su preparacion, composiciones farmacéuticas conteniendo dichas formas cristalinas, y a su uso en métodos de diagnostico o, de preferencia para el tratamiento terapéutico de animales de sangre caliente, en especial seres humanos, su uso como un intermediario o para la preparacion de las preparaciones farmacéuticas para utilizarse en métodos de diagnostico o, de preferencia, para el tratamiento terapéutico de animales de sangre caliente, en especial seres humanos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86648306P | 2006-11-20 | 2006-11-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY30728A1 true UY30728A1 (es) | 2008-07-03 |
Family
ID=39345299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY30728A UY30728A1 (es) | 2006-11-20 | 2007-11-20 | Sales y formas de cristal del 2-metil-[4-(3-metil-2-oxo-8-quinolin-3-il-2,3-dihidro-imidazo-[4,5-c]-quinolin-1-il-fenil]propionitrilo |
Country Status (36)
Country | Link |
---|---|
US (2) | US8436177B2 (es) |
EP (2) | EP2094700B1 (es) |
JP (2) | JP5562033B2 (es) |
KR (3) | KR20140129396A (es) |
CN (5) | CN106045993A (es) |
AR (1) | AR064256A1 (es) |
AU (1) | AU2007323820B2 (es) |
BR (1) | BRPI0719112A2 (es) |
CA (1) | CA2669199C (es) |
CL (1) | CL2007003316A1 (es) |
CO (1) | CO6382134A2 (es) |
CR (1) | CR10757A (es) |
DO (1) | DOP2009000116A (es) |
EA (1) | EA015677B1 (es) |
EC (1) | ECSP099340A (es) |
GE (1) | GEP20125436B (es) |
GT (1) | GT200900133A (es) |
HK (1) | HK1132739A1 (es) |
HR (1) | HRP20140627T1 (es) |
IL (2) | IL198467A (es) |
JO (1) | JO2903B1 (es) |
MA (1) | MA30967B1 (es) |
MX (1) | MX2009005360A (es) |
MY (1) | MY150216A (es) |
NI (1) | NI200900091A (es) |
NO (1) | NO20092227L (es) |
NZ (1) | NZ576357A (es) |
PE (2) | PE20120083A1 (es) |
PH (1) | PH12013502100A1 (es) |
RS (1) | RS53335B (es) |
SM (1) | SMP200900041B (es) |
TN (1) | TN2009000191A1 (es) |
TW (2) | TW201402567A (es) |
UA (1) | UA98473C2 (es) |
UY (1) | UY30728A1 (es) |
WO (1) | WO2008064093A2 (es) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
JP5869222B2 (ja) | 2008-01-04 | 2016-02-24 | インテリカイン, エルエルシー | 特定の化学的実体、組成物および方法 |
MX2010010505A (es) * | 2008-03-26 | 2010-10-26 | Novartis Ag | Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf). |
CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
NZ596487A (en) | 2009-06-04 | 2012-11-30 | Novartis Ag | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES AND THE USE THEREOF AS PI3K INHIBITORS |
NZ601581A (en) | 2010-02-03 | 2014-03-28 | Signal Pharm Llc | Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors |
AU2011255218B2 (en) | 2010-05-21 | 2015-03-12 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
DE102010035744A1 (de) * | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 複素環化合物及びその使用 |
CA2824197C (en) * | 2011-01-10 | 2020-02-25 | Michael Martin | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
CA2842190A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
CN103930422A (zh) | 2011-07-19 | 2014-07-16 | 无限药品股份有限公司 | 杂环化合物及其用途 |
AR091790A1 (es) | 2011-08-29 | 2015-03-04 | Infinity Pharmaceuticals Inc | Derivados de isoquinolin-1-ona y sus usos |
EA201490725A1 (ru) * | 2011-09-30 | 2014-11-28 | Дана-Фарбер Кэнсер Инститьют, Инк. | Способ лечения мукоэпидермоидной карциномы |
JP6077642B2 (ja) | 2012-04-10 | 2017-02-08 | シャンハイ インリ ファーマシューティカル カンパニー リミティド | 縮合ピリミジン化合物、その調製法、中間体、組成物、及び使用 |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
NZ712184A (en) * | 2013-03-21 | 2020-01-31 | Array Biopharma Inc | Combination therapy comprising a b-raf inhibitor and a second inhibitor |
CN105324381A (zh) | 2013-04-17 | 2016-02-10 | 西格诺药品有限公司 | 有关1-乙基-7-(2-甲基-6-(1H-1,2,4-三唑-3-基)吡啶-3-基)-3,4-二氢吡嗪并[2,3-b]吡嗪-2(1H)-酮的药物制剂、程序、固体形式和使用方法 |
UA115805C2 (uk) | 2013-04-17 | 2017-12-26 | Сігнал Фармасьютікалз, Елелсі | Комбінована терапія, яка включає сполуку дигідропіразинопіразину й антагоніст рецептора андрогену, для лікування раку простати |
NZ631082A (en) | 2013-04-17 | 2017-06-30 | Signal Pharm Llc | Methods for treating cancer using tor kinase inhibitor combination therapy |
AU2014254057A1 (en) | 2013-04-17 | 2015-11-05 | Signal Pharmaceuticals, Llc | Combination therapy comprising a TOR kinase inhibitor and N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer |
US9505764B2 (en) | 2013-04-17 | 2016-11-29 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
CA2908353C (en) | 2013-04-17 | 2021-11-02 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
WO2014172436A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
JP6401250B2 (ja) | 2013-05-29 | 2018-10-10 | シグナル ファーマシューティカルズ,エルエルシー | 7−(6−(2−ヒドロキシプロパン−2−イル)ピリジン−3−イル)−1−((trans)−4−メトキシシクロヘキシル)−3,4−ジヒドロピラジノ[2,3−b]ピラジン−2(1H)−オン、その固体形態の医薬組成物、及びその使用方法 |
US9745321B2 (en) | 2013-09-30 | 2017-08-29 | Shanghai Yingli Pharmaceutical Co., Ltd | Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MX2016004340A (es) | 2013-10-04 | 2016-08-08 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos. |
CA2926596C (en) | 2013-10-16 | 2020-07-14 | Shanghai Yingli Pharmaceutical Co., Ltd | Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof |
PT3119397T (pt) | 2014-03-19 | 2022-04-11 | Infinity Pharmaceuticals Inc | Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
JP2017511367A (ja) | 2014-04-16 | 2017-04-20 | シグナル ファーマシューティカルズ,エルエルシー | 1−エチル−7−(2−メチル−6−(1H−1,2,4−トリアゾール−3−イル)ピリジン−3−イル)−3,4−ジヒドロピラジノ[2,3−b]ピラジン−2(1H)−オン及び共形成物を含む固体形態、その組成物及び使用方法 |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
EP3297629A1 (en) | 2015-05-20 | 2018-03-28 | Novartis AG | Pharmaceutical combination of everolimus with dactolisib |
US10160761B2 (en) | 2015-09-14 | 2018-12-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MX2018016227A (es) | 2016-06-24 | 2019-07-08 | Infinity Pharmaceuticals Inc | Terapias de combinacion. |
MX2019006090A (es) | 2016-11-23 | 2019-08-21 | Novartis Ag | Metodos para mejorar la respuesta inmune con everolimus, dactolisib o ambos. |
EP3641772B1 (en) | 2017-06-22 | 2023-08-02 | Celgene Corporation | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
CN111187181B (zh) * | 2019-11-22 | 2023-05-05 | 吉林大学 | 一种2-(4-氨基苯基)-2-甲基丙腈化合物的制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | 1h―イミダゾピリジン誘導体 |
GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
AR046845A1 (es) | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
AU2004295061B2 (en) * | 2003-11-21 | 2008-11-20 | Novartis Ag | 1H-imidazoquinoline derivatives as protein kinase inhibitors |
WO2006000020A1 (en) | 2004-06-29 | 2006-01-05 | European Nickel Plc | Improved leaching of base metals |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
-
2007
- 2007-11-16 EP EP07864492.9A patent/EP2094700B1/en active Active
- 2007-11-16 EP EP10176298A patent/EP2364981A1/en not_active Withdrawn
- 2007-11-16 KR KR1020147029446A patent/KR20140129396A/ko not_active Application Discontinuation
- 2007-11-16 US US12/514,976 patent/US8436177B2/en active Active
- 2007-11-16 AR ARP070105114A patent/AR064256A1/es unknown
- 2007-11-16 MX MX2009005360A patent/MX2009005360A/es active IP Right Grant
- 2007-11-16 UA UAA200905006A patent/UA98473C2/ru unknown
- 2007-11-16 KR KR1020147014039A patent/KR20140091718A/ko not_active Application Discontinuation
- 2007-11-16 EA EA200900638A patent/EA015677B1/ru not_active IP Right Cessation
- 2007-11-16 CN CN201610405653.7A patent/CN106045993A/zh active Pending
- 2007-11-16 CN CNA2007800420773A patent/CN101541793A/zh active Pending
- 2007-11-16 KR KR1020097010203A patent/KR20090080530A/ko not_active Application Discontinuation
- 2007-11-16 CN CN2012102686473A patent/CN102993202A/zh active Pending
- 2007-11-16 RS RS20140278A patent/RS53335B/en unknown
- 2007-11-16 JP JP2009537381A patent/JP5562033B2/ja not_active Expired - Fee Related
- 2007-11-16 MY MYPI20091920A patent/MY150216A/en unknown
- 2007-11-16 CN CN201910073048.8A patent/CN109970735A/zh active Pending
- 2007-11-16 GE GEAP200711260A patent/GEP20125436B/en unknown
- 2007-11-16 NZ NZ576357A patent/NZ576357A/en not_active IP Right Cessation
- 2007-11-16 AU AU2007323820A patent/AU2007323820B2/en not_active Ceased
- 2007-11-16 WO PCT/US2007/084893 patent/WO2008064093A2/en active Application Filing
- 2007-11-16 CN CN2011103337901A patent/CN102336752A/zh active Pending
- 2007-11-16 CA CA2669199A patent/CA2669199C/en not_active Expired - Fee Related
- 2007-11-16 BR BRPI0719112-0A patent/BRPI0719112A2/pt not_active IP Right Cessation
- 2007-11-19 PE PE2011001508A patent/PE20120083A1/es not_active Application Discontinuation
- 2007-11-19 CL CL200703316A patent/CL2007003316A1/es unknown
- 2007-11-19 JO JO2007482A patent/JO2903B1/en active
- 2007-11-19 TW TW102134663A patent/TW201402567A/zh unknown
- 2007-11-19 PE PE2007001607A patent/PE20081780A1/es not_active Application Discontinuation
- 2007-11-19 TW TW096143742A patent/TWI417292B/zh not_active IP Right Cessation
- 2007-11-20 UY UY30728A patent/UY30728A1/es not_active Application Discontinuation
-
2009
- 2009-04-29 CR CR10757A patent/CR10757A/es unknown
- 2009-04-30 IL IL198467A patent/IL198467A/en not_active IP Right Cessation
- 2009-05-15 TN TNP2009000191A patent/TN2009000191A1/fr unknown
- 2009-05-18 NI NI200900091A patent/NI200900091A/es unknown
- 2009-05-18 GT GT200900133A patent/GT200900133A/es unknown
- 2009-05-18 EC EC2009009340A patent/ECSP099340A/es unknown
- 2009-05-18 CO CO09050683A patent/CO6382134A2/es active IP Right Grant
- 2009-05-19 DO DO2009000116A patent/DOP2009000116A/es unknown
- 2009-05-28 SM SM200900041T patent/SMP200900041B/it unknown
- 2009-06-03 MA MA31947A patent/MA30967B1/fr unknown
- 2009-06-09 NO NO20092227A patent/NO20092227L/no not_active Application Discontinuation
-
2010
- 2010-01-08 HK HK10100151.3A patent/HK1132739A1/xx not_active IP Right Cessation
-
2012
- 2012-05-17 IL IL219877A patent/IL219877A0/en unknown
-
2013
- 2013-04-04 US US13/856,458 patent/US20130289064A1/en not_active Abandoned
- 2013-05-13 JP JP2013101604A patent/JP2013173788A/ja active Pending
- 2013-10-10 PH PH12013502100A patent/PH12013502100A1/en unknown
-
2014
- 2014-07-01 HR HRP20140627TT patent/HRP20140627T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY30728A1 (es) | Sales y formas de cristal del 2-metil-[4-(3-metil-2-oxo-8-quinolin-3-il-2,3-dihidro-imidazo-[4,5-c]-quinolin-1-il-fenil]propionitrilo | |
ECSP088217A (es) | Formas de cristal delta y épsilon de mesilato de imatinib | |
SV2007002813A (es) | Compuestos para la modulacion de la actividad del c-fms y/o el c-kit y sus usos aplicables | |
ECSP11011113A (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
ECSP088329A (es) | Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8 | |
UY29964A1 (es) | Formas de cristal f,g,h,i, y k del mesilato de imatinib | |
ECSP12007431A (es) | Compuestos orgánicos | |
CR20110216A (es) | Derivados de ácido 1-amino-2-ciclobutiletilborónico | |
CR9781A (es) | 1h-imidazopiridinas sustituidas con hidroxi y procedimientos | |
CL2008003096A1 (es) | Compuestos derivados de piperidino-dihidrotienopirimidinas; inhibidores pde4; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos o enfermedades de las vias respiratorias o gastrointestinales, como tambien enfermedades inflamatorias de las articulaciones u ojos, entre otras. | |
GT200500360A (es) | Compuestos organicos | |
CL2007003187A1 (es) | Compuestos derivados de bencil-benzonitrilo sustituido con glucopiranosilo y sus sales; procedimiento de preparacion; compuestos intermediarios; proceso para preparar los compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de | |
DOP2006000169A (es) | Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
GT200600316A (es) | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. | |
GT200600045A (es) | Derivados de piridizina y su uso como agentes terapeuticos | |
GT201300080A (es) | Proceso de elaboracion para derivados de pirimidina | |
UY29469A1 (es) | Compuestos sulfoximino-macrocíclicos y sus sales, composiciones farmacéuticas que comprenden dichos compuestos, métodos de preparación y usos de los mismos. | |
UY29818A1 (es) | Nuevos compuestos de azetidina, composiciones farmaceuticas que los contienen, procesos de preparacion y sus usos terapeuticos | |
PA8720801A1 (es) | Nuevas combinaciones terapeuticas para el tratamiento de la depresion | |
UY29433A1 (es) | Compuestos de esteres benzoicos, composiciones, usos y métodos | |
CL2011003144A1 (es) | Forma cristalina e3 de bisulfato de atazanavir; composicion farmaceutica que la comprende; util para el tratamiento de enfermedades originadas por retrovirus (divisional de la solicitud 1057-05). | |
CO7151509A2 (es) | Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1 | |
CO7131369A2 (es) | 5-amino[1,4]tiazinas como inhibidores de bace1 | |
CO6541577A2 (es) | Nuevas formas polimorfas de {4.6- diamino -2-[1-(2-fluorobencil)-1h- pirazolo[3.4-b]piridin-3il] pirimidin -5il} carbamato de metilo | |
CL2011001829A1 (es) | 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20170731 |